CR11419A - Formulaciones de polvo seco que comprenden derivados del acido ascorbico - Google Patents

Formulaciones de polvo seco que comprenden derivados del acido ascorbico

Info

Publication number
CR11419A
CR11419A CR11419A CR11419A CR11419A CR 11419 A CR11419 A CR 11419A CR 11419 A CR11419 A CR 11419A CR 11419 A CR11419 A CR 11419A CR 11419 A CR11419 A CR 11419A
Authority
CR
Costa Rica
Prior art keywords
dry powder
ascorbic acid
powder formulations
include derivatives
formulations
Prior art date
Application number
CR11419A
Other languages
English (en)
Inventor
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11419A publication Critical patent/CR11419A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion proporciona formulaciones de polvo seco que comprenden un derivado del acido ascorbico que presenta un comportamiento inhalatorio bueno e inhaladores de polvo seco que las contienen.
CR11419A 2007-11-07 2010-05-07 Formulaciones de polvo seco que comprenden derivados del acido ascorbico CR11419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98602607P 2007-11-07 2007-11-07
US7344308P 2008-06-18 2008-06-18

Publications (1)

Publication Number Publication Date
CR11419A true CR11419A (es) 2010-08-27

Family

ID=40626004

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11419A CR11419A (es) 2007-11-07 2010-05-07 Formulaciones de polvo seco que comprenden derivados del acido ascorbico

Country Status (17)

Country Link
US (1) US20110105449A1 (es)
EP (1) EP2217278A1 (es)
JP (1) JP2011503058A (es)
KR (1) KR20100095437A (es)
CN (1) CN101909652A (es)
AU (1) AU2008325290B2 (es)
BR (1) BRPI0819259A2 (es)
CA (1) CA2704639A1 (es)
CO (1) CO6270343A2 (es)
CR (1) CR11419A (es)
DO (1) DOP2010000138A (es)
EA (1) EA201000677A1 (es)
EC (1) ECSP10010164A (es)
IL (1) IL205514A0 (es)
MX (1) MX2010005036A (es)
WO (1) WO2009061273A1 (es)
ZA (1) ZA201003223B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104257610A (zh) 2010-04-01 2015-01-07 奇斯药制品公司 用于制备可吸入干粉所用的载体颗粒的方法
CN102302488A (zh) * 2011-07-06 2012-01-04 中山大学 一种针对ccl18靶标的化合物在制备抗乳腺癌药物中的应用
WO2014007773A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and sorbitol
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
JP5087182B1 (ja) 2012-06-13 2012-11-28 クリニプロ株式会社 吸入用パウダーの製造方法
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
DK3689332T3 (da) 2014-09-09 2026-03-23 Vectura Ltd Formulering, som omfatter glycopyrrolat, fremgangsmåde og apparat
EA201792159A1 (ru) * 2015-04-01 2018-01-31 Люпин Атлантис Холдингс Са Способ получения сухих порошкообразных смесей

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071963A (en) * 1996-11-06 2000-06-06 Roche Vitamins Inc. Water dispersible compositions
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
EP1326642A2 (en) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
US20020085978A1 (en) * 2000-11-10 2002-07-04 Mina Buenafe Degradation-resistant glucocorticosteroid formulations
US20020165207A1 (en) * 2001-05-02 2002-11-07 Richard Rosenbloom Compositions and methods for the treatment of diabetic neuropathy
CN101098678A (zh) * 2004-04-23 2008-01-02 锡德克斯公司 含有磺基烷基醚环糊精的dpi制剂
EP2311793A1 (en) * 2004-12-17 2011-04-20 Cipla Ltd. Crystalline levosalbutamol sulphate (Form II)

Also Published As

Publication number Publication date
AU2008325290A1 (en) 2009-05-14
WO2009061273A1 (en) 2009-05-14
MX2010005036A (es) 2010-05-27
US20110105449A1 (en) 2011-05-05
EP2217278A1 (en) 2010-08-18
KR20100095437A (ko) 2010-08-30
AU2008325290B2 (en) 2011-12-08
CA2704639A1 (en) 2009-05-14
BRPI0819259A2 (pt) 2019-10-01
DOP2010000138A (es) 2010-06-15
ECSP10010164A (es) 2010-06-29
JP2011503058A (ja) 2011-01-27
IL205514A0 (en) 2010-12-30
CN101909652A (zh) 2010-12-08
CO6270343A2 (es) 2011-04-20
EA201000677A1 (ru) 2010-12-30
ZA201003223B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CR11419A (es) Formulaciones de polvo seco que comprenden derivados del acido ascorbico
CR20130663A (es) Composiciones farmcéuticas inhalables
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
MX339408B (es) Composiciones farmaceuticas entericas resistentes al alcohol.
EP3600563C0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING VITAMIN D3 AND HYALURONIC ACID
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
SI1818057T1 (sl) Stabilne farmacevtske formulacije montelukast natrija
AR067309A1 (es) Formulaciones farmaceuticas que contienen derivados de acido lipoico
CR10900A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20140505A (es) (r) -nifuratel y sintesis de (r) - nifuratel
CR10050A (es) Combinacion fungicida de productos activos
MY181719A (en) Fragrance and flavor compositions comprising neopentyl glycol diacetate
ATE429906T1 (de) Trockene aripiprazolformulierungen
MX2014015199A (es) Formulacion de pexiganan estable.
CR11439A (es) Composiciones para inhalacion comprendiendo acido montelukast y un inhibidor pde-4 o un corticosteroide inhalado
BR112014003790A2 (pt) ambientador de ar de carragenina em gel
MX365429B (es) Formulacion de aroma y fragancia (i).
BRPI0913093A2 (pt) Compostos derivados de [4-(1-amino-etil)-cicloexil]- metil-amina e [6-(1-amino-etil)-tetraidro-piran-3-il]- metil-amina, medicamento, composição farmacêutica que contêm esse composto e uso dos mesmos
BR112017006816A2 (pt) dispositivo de inalação.
CU20100090A7 (es) Formulaciones de polvo seco que comprenden derivados del ácido ascórbico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)